{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T06:14:53Z","timestamp":1788329693081,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Key Project of the Health Commission of Hunan Province"},{"name":"Guiding Plan Project of Hengyang City"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04943-4","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T05:41:54Z","timestamp":1788327714000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Trastuzumab treatment is associated with ferroptosis-related alterations in HER2-positive breast cancer organoids"],"prefix":"10.1007","volume":"96","author":[{"given":"Ming","family":"Lei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunsong","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1893-2477","authenticated-orcid":false,"given":"Dan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"issue":"4","key":"4943_CR1","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","volume":"31","author":"J Kim","year":"2025","unstructured":"Kim J et al (2025) Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat Med 31(4):1154\u20131162","journal-title":"Nat Med"},{"key":"4943_CR2","doi-asserted-by":"publisher","first-page":"1385571","DOI":"10.3389\/fimmu.2024.1385571","volume":"15","author":"Z Niu","year":"2024","unstructured":"Niu Z et al (2024) CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies. Front Immunol 15:1385571","journal-title":"Front Immunol"},{"issue":"1","key":"4943_CR3","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12885-023-10634-7","volume":"23","author":"Q Shi","year":"2023","unstructured":"Shi Q et al (2023) Distribution, dynamic evolution, and clinical outcomes of patients with advanced breast cancer according to HER2 expression. BMC Cancer 23(1):173","journal-title":"BMC Cancer"},{"issue":"1","key":"4943_CR4","doi-asserted-by":"publisher","first-page":"11008","DOI":"10.1038\/s41598-023-38200-y","volume":"13","author":"YJ Kang","year":"2023","unstructured":"Kang YJ et al (2023) Predictive biological factors for late survival in patients with HER2-positive breast cancer. Sci Rep 13(1):11008","journal-title":"Sci Rep"},{"issue":"21","key":"4943_CR5","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1158\/0008-5472.CAN-23-4066","volume":"84","author":"YW Li","year":"2024","unstructured":"Li YW et al (2024) Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies. Cancer Res 84(21):3669\u20133683","journal-title":"Cancer Res"},{"issue":"17","key":"4943_CR6","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.3390\/cells13171452","volume":"13","author":"B Nami","year":"2024","unstructured":"Nami B, Wang Z (2024) A Non-Canonical p75HER2 Signaling Pathway Underlying Trastuzumab Action and Resistance in Breast Cancer. Cells 13(17):1452","journal-title":"Cells"},{"issue":"5","key":"4943_CR7","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41416-019-0635-y","volume":"122","author":"FW Hunter","year":"2020","unstructured":"Hunter FW et al (2020) Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. Br J Cancer 122(5):603\u2013612","journal-title":"Br J Cancer"},{"issue":"1","key":"4943_CR8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12943-023-01716-y","volume":"22","author":"F Xing","year":"2023","unstructured":"Xing F et al (2023) CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer. Mol Cancer 22(1):6","journal-title":"Mol Cancer"},{"issue":"1","key":"4943_CR9","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41420-025-02328-9","volume":"11","author":"G Eskander","year":"2025","unstructured":"Eskander G et al (2025) Insights on the crosstalk among different cell death mechanisms. Cell Death Discov 11(1):56","journal-title":"Cell Death Discov"},{"issue":"3","key":"4943_CR10","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3390\/ph18030334","volume":"18","author":"H Wang","year":"2025","unstructured":"Wang H, Xie Y (2025) Advances in Ferroptosis Research: A Comprehensive Review of Mechanism Exploration, Drug Development, and Disease Treatment. Pharmaceuticals (Basel) 18(3):334","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"4943_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12943-022-01530-y","volume":"21","author":"C Zhang","year":"2022","unstructured":"Zhang C et al (2022) Ferroptosis in cancer therapy: a novel approach to reversing drug resistance. Mol Cancer 21(1):47","journal-title":"Mol Cancer"},{"issue":"1","key":"4943_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41392-024-01769-5","volume":"9","author":"Q Zhou","year":"2024","unstructured":"Zhou Q et al (2024) Ferroptosis in cancer: From molecular mechanisms to therapeutic strategies. Signal Transduct Target Ther 9(1):55","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"4943_CR13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41419-025-07354-0","volume":"16","author":"J Cao","year":"2025","unstructured":"Cao J et al (2025) Targeting estrogen-regulated system x(c)(-) promotes ferroptosis and endocrine sensitivity of ER+ breast cancer. Cell Death Dis 16(1):30","journal-title":"Cell Death Dis"},{"issue":"7545","key":"4943_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature14344","volume":"520","author":"L Jiang","year":"2015","unstructured":"Jiang L et al (2015) Ferroptosis as a p53-mediated activity during tumour suppression. Nature 520(7545):57\u201362","journal-title":"Nature"},{"issue":"11","key":"4943_CR15","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.medj.2024.08.010","volume":"5","author":"L Tong","year":"2024","unstructured":"Tong L et al (2024) Patient-derived organoids in precision cancer medicine. Med 5(11):1351\u20131377","journal-title":"Med"},{"key":"4943_CR16","doi-asserted-by":"publisher","first-page":"1422031","DOI":"10.3389\/fimmu.2024.1422031","volume":"15","author":"Y Yang","year":"2024","unstructured":"Yang Y et al (2024) Organoids: new frontiers in tumor immune microenvironment research. Front Immunol 15:1422031","journal-title":"Front Immunol"},{"key":"4943_CR17","doi-asserted-by":"publisher","first-page":"115803","DOI":"10.1016\/j.bcp.2023.115803","volume":"217","author":"YT Tzeng","year":"2023","unstructured":"Tzeng YT et al (2023) Breast cancer organoids derived from patients: A platform for tailored drug screening. Biochem Pharmacol 217:115803","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"4943_CR18","doi-asserted-by":"publisher","first-page":"e006290","DOI":"10.1136\/jitc-2022-006290","volume":"11","author":"L Magr\u00e9","year":"2023","unstructured":"Magr\u00e9 L et al (2023) Emerging organoid-immune co-culture models for cancer research: from oncoimmunology to personalized immunotherapies. J Immunother Cancer 11(5):e006290","journal-title":"J Immunother Cancer"},{"issue":"9","key":"4943_CR19","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41571-024-00924-9","volume":"21","author":"J Yoon","year":"2024","unstructured":"Yoon J, Oh DY (2024) HER2-targeted therapies beyond breast cancer - an update. Nat Rev Clin Oncol 21(9):675\u2013700","journal-title":"Nat Rev Clin Oncol"},{"key":"4943_CR20","doi-asserted-by":"publisher","first-page":"e076065","DOI":"10.1136\/bmj-2023-076065","volume":"383","author":"F Ma","year":"2023","unstructured":"Ma F et al (2023) Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial. BMJ 383:e076065","journal-title":"BMJ"},{"issue":"2","key":"4943_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/bcr3621","volume":"16","author":"M Barok","year":"2014","unstructured":"Barok M, Joensuu H, Isola J (2014) Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res 16(2):209","journal-title":"Breast Cancer Res"},{"issue":"5","key":"4943_CR22","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.hlife.2024.05.002","volume":"3","author":"Y Zhang","year":"2025","unstructured":"Zhang Y et al (2025) Cancer research revolutionized: Unveiling the power of organoids and their therapeutic potential in oncology. hLife 3(5):216\u2013236","journal-title":"hLife"},{"issue":"6","key":"4943_CR23","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1038\/s41592-025-02685-4","volume":"22","author":"HT Ong","year":"2025","unstructured":"Ong HT et al (2025) Digitalized organoids: integrated pipeline for high-speed 3D analysis of organoid structures using multilevel segmentation and cellular topology. Nat Methods 22(6):1343\u20131354","journal-title":"Nat Methods"},{"key":"4943_CR24","doi-asserted-by":"publisher","first-page":"1629620","DOI":"10.3389\/fimmu.2025.1629620","volume":"16","author":"Z Shan","year":"2025","unstructured":"Shan Z, Liu F (2025) Targeting ferroptosis, pyroptosis and necroptosis for cancer immunotherapy in melanoma: mechanistic insights and clinical perspectives. Front Immunol 16:1629620","journal-title":"Front Immunol"},{"issue":"1","key":"4943_CR25","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40880-018-0288-x","volume":"38","author":"P Koppula","year":"2018","unstructured":"Koppula P et al (2018) Amino acid transporter SLC7A11\/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer. Cancer Commun (Lond) 38(1):12","journal-title":"Cancer Commun (Lond)"},{"key":"4943_CR26","doi-asserted-by":"publisher","first-page":"116512","DOI":"10.1016\/j.biopha.2024.116512","volume":"174","author":"W Zhang","year":"2024","unstructured":"Zhang W et al (2024) GPX4, ferroptosis, and diseases. Biomed Pharmacother 174:116512","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"4943_CR27","doi-asserted-by":"publisher","first-page":"188890","DOI":"10.1016\/j.bbcan.2023.188890","volume":"1878","author":"Y Liu","year":"2023","unstructured":"Liu Y et al (2023) GPX4: The hub of lipid oxidation, ferroptosis, disease and treatment. Biochim Biophys Acta Rev Cancer 1878(3):188890","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"1","key":"4943_CR28","doi-asserted-by":"publisher","first-page":"e23507","DOI":"10.1016\/j.heliyon.2023.e23507","volume":"10","author":"Z Chen","year":"2024","unstructured":"Chen Z et al (2024) The application of approaches in detecting ferroptosis. Heliyon 10(1):e23507","journal-title":"Heliyon"},{"issue":"14","key":"4943_CR29","first-page":"4132","volume":"62","author":"FM Yakes","year":"2002","unstructured":"Yakes FM et al (2002) Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 62(14):4132\u20134141","journal-title":"Cancer Res"},{"issue":"5","key":"4943_CR30","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ccr.2009.03.020","volume":"15","author":"TT Junttila","year":"2009","unstructured":"Junttila TT et al (2009) Ligand-independent HER2\/HER3\/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15(5):429\u2013440","journal-title":"Cancer Cell"},{"issue":"1","key":"4943_CR31","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/proteomes13010006","volume":"13","author":"S Gupta","year":"2025","unstructured":"Gupta S et al (2025) DNA Damage-Induced Ferroptosis: A Boolean Model Regulating p53 and Non-Coding RNAs in Drug Resistance. Proteomes 13(1):6","journal-title":"Proteomes"},{"issue":"1","key":"4943_CR32","doi-asserted-by":"publisher","first-page":"21916","DOI":"10.1038\/s41598-023-49136-8","volume":"13","author":"M Lei","year":"2023","unstructured":"Lei M et al (2023) Gankyrin inhibits ferroptosis through the p53\/SLC7A11\/GPX4 axis in triple-negative breast cancer cells. Sci Rep 13(1):21916","journal-title":"Sci Rep"},{"key":"4943_CR33","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.freeradbiomed.2018.05.074","volume":"133","author":"R Kang","year":"2019","unstructured":"Kang R, Kroemer G, Tang D (2019) The tumor suppressor protein p53 and the ferroptosis network. Free Radic Biol Med 133:162\u2013168","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"4943_CR34","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/s41598-020-58051-1","volume":"10","author":"J Zhu","year":"2020","unstructured":"Zhu J et al (2020) Pifithrin-\u03b1 alters p53 post-translational modifications pattern and differentially inhibits p53 target genes. Sci Rep 10(1):1049","journal-title":"Sci Rep"},{"key":"4943_CR35","doi-asserted-by":"publisher","first-page":"100947","DOI":"10.1016\/j.drup.2023.100947","volume":"68","author":"R Du","year":"2023","unstructured":"Du R et al (2023) PDPN positive CAFs contribute to HER2 positive breast cancer resistance to trastuzumab by inhibiting antibody-dependent NK cell-mediated cytotoxicity. Drug Resist Updat 68:100947","journal-title":"Drug Resist Updat"},{"issue":"1","key":"4943_CR36","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13045-020-00946-7","volume":"13","author":"R Tang","year":"2020","unstructured":"Tang R et al (2020) Ferroptosis, necroptosis, and pyroptosis in anticancer immunity. J Hematol Oncol 13(1):110","journal-title":"J Hematol Oncol"},{"key":"4943_CR37","doi-asserted-by":"publisher","first-page":"111869","DOI":"10.1016\/j.cellsig.2025.111869","volume":"134","author":"B Wang","year":"2025","unstructured":"Wang B et al (2025) Role of ferroptosis in breast cancer: Molecular mechanisms and therapeutic interventions. Cell Signal 134:111869","journal-title":"Cell Signal"},{"key":"4943_CR38","doi-asserted-by":"publisher","first-page":"1499125","DOI":"10.3389\/fonc.2024.1499125","volume":"14","author":"C Peng","year":"2024","unstructured":"Peng C, Chen Y, Jiang M (2024) Targeting ferroptosis: a promising strategy to overcome drug resistance in breast cancer. Front Oncol 14:1499125","journal-title":"Front Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04943-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04943-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04943-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T05:41:55Z","timestamp":1788327715000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04943-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4943"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04943-4","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"12 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study obtained informed consent from all patients who provided samples and was approved by the Hengyang Maternal and Child Health Hospital Ethics Committee (approval number 202110). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors used language-editing assistance only to improve grammar and readability. All scientific content, interpretation, and conclusions were reviewed and approved by the authors, who take full responsibility for the final manuscript.","order":3,"name":"Ethics","label":"Artificial intelligence statements","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"96"}}